| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| CT ORDER | CT ORDER |
Other
|
||
| 424B3 | Form of prospectus reflecting facts events constituting substantive change from last form |
Registration Statements
|
||
| EFFECT | EFFECT |
Other
|
||
| S-4/A | Pre-effective amendment to an S-4 filing |
Registration Statements
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| CORRESP | CORRESP |
Other
|
||
| S-4/A | Pre-effective amendment to an S-4 filing |
Registration Statements
|
EX-101.INS - XBRL INSTANCE DOCUMENT |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
